Lake, MD 8:00

– 8:10 AM Introduction and Why the First Quarter? John R. Lake, MD 8:10 – 8:30 AM Justification for Routine Intensive Care after Liver Transplantation Michael A. Ramsay, MD 8:30 – 8:50 AM Early Graft Dysfunction: Causes, Recognition and Management Marc Deschenes, MD buy PLX4032 8:50 – 9:10 AM Small-for-Size Syndrome: Recognition and Management Chung-Mau Lo, MD 9:10 – 9:30 AM How Relevant is Acute Cellular Rejection? Michael R. Charlton, MD 9:30 – 9:50 AM Hepatic Artery Thrombosis: Conservative Management or Retransplantation? Nigel Heaton, MB, FRCS 9:50 – 10:10 AM Discussion 10:10 -10:30 AM Break Session II: Quarter 1-Investigation of Graft Dysfunction MODERATOR: John R. Lake, MD 10:30 – 10:50 AM Systematic Investigation of Elevated Transaminases during the Third Posttransplant Month Michael P.

Curry, MD 10:50 – 11:10 AM Systematic Investigation of Elevated Cholestatic Enzymes during the Third Post-transplant Month Andrew L. Mason, MBBS, MRCPI 11:10 -11:25 AM Specific Contribution selleckchem of the Histopathologist Stefan G. Hubscher, MD 11:25 – 11:40 AM Specific Contribution of the Advanced Endoscopist Mustafa A. Arain, MD 11:40 AM – Noon Discussion Noon – 1:00 PM Lunch Session III: Second Decade MODERATOR: John O’Grady, MD 1:00 – 1:05 PM Why the Second Decade? John G. O’Grady, MD 1:05 – 1:20 PM Will Retransplantation be the Norm for Pediatric Recipients with Ambitions for Grand-parenthood? Deirdre A. Kelly, MD 1:20 -1:40 PM Adolescence – Challenges and Responses Sue

V. McDiarmid, MD 1:40 – 1:55 PM Long Term Quality of life in Transplant Recipients Patrizia 上海皓元 Burra, MD, PhD 1:55 – 2:15 PM Tolerance Profiles and Immunosuppression Alberto Sanchez-Fueyo, MD 2:15 – 2:25 PM Is Disease Recurrence Still Relevant to Graft Survival? James F. Trotter, MD 2:25 – 2:45 PM Extrahepatic Implications of the Metabolic Syndrome Kymberly D. Watt, MD 2:45 – 3:05 PM Malignant Disease – Risk and Surveillance Strategies Geoffrey W. McCaughan, MD, PhD 3:05 – 3:30 PM Discussion AASLD/NASPGHAN Pediatric Symposium Friday, November 1 Noon – 3:00 PM Room 150A New Insights and Controversies in Liver-based Metabolic Diseases COURSE DIRECTORS: Udeme D. Ekong, MD Simon Horslen, MD 3 CME Credits The purpose of the program is to review the advances made in the last 10-years within the field of metabolic liver diseases. This program will also offer the opportunity to review the pathophysiology of liver based metabolic disorders while gaining insights into the latest treatments available for management of these disorders. It will also specifically address candidacy for treatment and counsel.